Search results
Results from the WOW.Com Content Network
It was named by the Health Service Journal as one of the top hundred NHS trusts to work for in 2015. 92% of staff recommend it as a place for treatment and 73% recommended it as a place to work. [35] In March 2023, it had 1,796 full-time equivalent staff [ 36 ] and a sickness absence rate of 4.7% compared to 4.9% average across England.
The patient's consultant must apply to the fund using an application form supplied by NHS England. Decision Summaries which are the formal decisions of the Chemotherapy Clinical Reference Group are published. [5] Avastin is the most frequently requested treatment. Kadcyla is the most expensive drug funded.
After a secret discount was agreed by Roche the Cancer Drugs Fund will continue to fund it. [27] In June 2017, the NHS Confederation and NHS Chief Executive Simon Stevens announced that the NHS would be offering trastuzumab emtansine to a limited number of women after striking a deal with Roche on the price. [30]
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Medway NHS Foundation Trust reported that fraudsters stole £500,000, but the majority – £420,000 – was later recovered. ... £19,000 from the fraudulent bank account. As far as we are aware ...
The Association of NHS Charities, operating as NHS Charities Together, is a network of over 230 charitable organisations that support the devolved National Health Service (NHS), their staff, patients, and communities in the United Kingdom. It acts as a collective voice for NHS charities, as well as coordinating national fundraising efforts.
The Velindre University NHS Trust (Welsh: Ymddiriedolaeth GIG Prifysgol Felindre) is an NHS Wales trust established in 1994 as a specialist provider of cancer services in Wales. It runs the Velindre Cancer Centre and the Welsh Blood Service. It also incorporates, on a hosted basis, the NHS Wales Shared Services Partnership (NWSSP).
Micrograph showing a PD-L1 positive non-small cell lung carcinoma. PD-L1 immunostain. As of 2019, pembrolizumab is used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a first-line treatment for metastatic bladder cancer in patients who cannot receive cisplatin-based chemotherapy and have high levels ...